Achim Rittmeyer
8 Papers
24 Citations
Achim Rittmeyer is an academic researcher. The author has contributed to research in topics: Lung cancer & Pemetrexed. The author has an hindex of 5, co-authored 8 publications.
Chat about Author
Papers
Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)
Fabrice Barlesi,Arnaud Scherpereel,Achim Rittmeyer,Antonio Pazzola,Neus Ferrer Tur,Joo Hang Kim,Myung-Ju Ahn,Joachim G.J.V. Aerts,Vera Gorbunova,Anders Vikström,Elaine K. Wong,Pablo Perez-Moreno,Lada Mitchell,Harry J.M. Groen +13 more
TL;DR: In an unselected population of patients with nonsquamous NSCLC who had achieved disease control with platinum-based chemotherapy plus bevacizumab,BevacIZumab plus pemetrexed maintenance was associated with a significant PFS benefit compared with bevacsizumabs alone.
331
Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
Fabrice Barlesi,Arnaud Scherpereel,Vera Gorbunova,Radj Gervais,Anders Vikström,Christos Chouaid,Antonio Chella,Jeong-Ho Kim,Myung-Ju Ahn,Martin Reck,Antonio Pazzola,H. T. Kim,Joachim G.J.V. Aerts,Claire Morando,Anderson Loundou,H. Groen,Achim Rittmeyer +16 more
TL;DR: In an unselected population of nsNSCLC patients achieving disease control on platinum-based induction therapy, maintenance with bevacizumab-pemetrexed was associated with a nonsignificant increase in OS over bevacsumab alone.
172
Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial.
Achim Rittmeyer,Arnaud Scherpereel,Vera Gorbunova,Radj Gervais,Anders Vikström,Christos Chouaid,Antonio Chella,Joo Hang Kim,Myung-Ju Ahn,Martin Reck,Antonio Pazzola,Heung Tae Kim,Joachim G.J.V. Aerts,Harry J.M. Groen,Claire Morando,Anderson Loundou,Fabrice Barlesi +16 more
TL;DR: AVAPERL was designed to evaluate the safety and efficacy of bevacizumab with or without pemetrexed as continuation maintenance treatment and demonstrated improved progression-free survival (PFS) and met the primary end point.
17
AVAPERL1 (MO22089): Maintenance (mtc) bevacizumab (bev) with or without pemetrexed (pem) in patients (pts) with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line (1L) bev-cisplatin (cis)-pem: Interim safety data.
Fabrice Barlesi,Arnaud Scherpereel,Radj Gervais,Vera Gorbunova,Anders Vikström,M-J. Ahn,Jonah Kim,Antonio Chella,Joachim G.J.V. Aerts,N. Ferrer,J. M. Trigo Perez,B. Lutiger,Achim Rittmeyer +12 more
TL;DR: 1L bev-cis-pem was well tolerated with a safety profile comparable to that of regimens indicated for use with bev; most AEs were G 1/2.
4
Immunogenicity and Safety of the Prame Cancer Immunotherapeutic in Non-Small Cell Lung Cancer (NSCLC): Phase I Dose Escalation Study
Jean-Louis Pujol,T. De Pas,Achim Rittmeyer,Bartosz Kubisa,Eric Vallières,Evgeny Levchenko,B. Salaun,N. Vanhoutte,Muriel Debois,Vincent Brichard +9 more
TL;DR: The PRAME cancer immunotherapeutic was well-tolerated and elicited similar humoral responses in all 3 cohorts and a trend for an increased cellular response was observed with increasing dose of recPRAME.
4